Clinical and experimental hepatologySep 11, 2026

New treatments for long-term liver diseases focusing on fat-related liver scarring

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 12, 2026

Abstract

Chronic liver diseases (CLDs) are increasingly driven by metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory-fibrotic form (MASH).

Effective pharmacological therapies to halt or reverse fibrosis progression in MASH are currently lacking.
Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), show promising metabolic and anti-inflammatory effects.
These therapies may also possess potential antifibrotic activity, making them candidates for treating various CLD phenotypes.
Current knowledge includes insights into the mechanisms of action of these drugs and their clinical trial outcomes.

Simplified

Chronic liver diseases (CLDs) represent a growing global health challenge, driven by the increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), its progressive inflammatory-fibrotic form (metabolic dysfunction-associated steatohepatitis - MASH), as well as viral infections, alcoholic liver disease, and autoimmune and cholestatic disorders. Despite intensive research, effective pharmacological therapies capable of halting or reversing fibrosis progression - particularly in MASH - remain lacking. In recent years, incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and a new generation of metabolic multi-agonists, have gained breakthrough significance. These agents demonstrate potent metabolic, anti-inflammatory, and anti-steatotic effects, as well as potential antifibrotic activity, making them promising candidates for the treatment of various CLD phenotypes, including MASLD/MASH-associated fibrosis. This review synthesizes current knowledge on the mechanisms of action of these drugs, clinical trial outcomes, and their potential application as novel, targeted therapies in CLDs.

Full Text

Full text is available at the source.

View Full Text ↗

New treatments for long-term liver diseases focusing on fat-related liver scarring

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief